In brief: EU approval for AZ’s Tagrisso

Tegsedi approved in US, triggering milestone payment for Ionis
Credit: Orawan Pattarawimonchai

The European Medicines Agency has approved AstraZeneca’s marketing authorisation application for its lung cancer treatment Tagrisso.

The approval is based on data from a Phase III trial in which Tagrisso significantly improved progression-free survival compared to current 1st-line epidermal growth factor receptor tyrosine kinase inhibitors, erlotinib or gefitinib.

It follows US approval in April.